The attenuation of glomerular hyperfiltration is posited to be a principal mechanism underlying the kidney protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in diabetic kidney disease. Notably, the impact of SGLT2 inhibitors on kidney hemodynamic function has been posited to vary between type 1 and type 2 diabetes. The study by Wada et al. documents that in an animal model of type 2 diabetes, SGLT2 inhibitors mitigate glomerular hyperfiltration predominantly through afferent arteriolar constriction, a process mediated by the adenosine/A1 receptor pathway. This observation is consistent with mechanisms identified in type 1 diabetes, arguing for similar methods in type 1 and 2 diabetes.

中文翻译：

---

解读 SGLT2 抑制对肾脏血流动力学的影响：将大鼠对 2 型糖尿病的见解转化为人类。


肾小球过度滤过的减弱被认为是钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂在糖尿病肾病中发挥肾脏保护作用的主要机制。值得注意的是，SGLT2 抑制剂对肾脏血流动力学功能的影响被认为在 1 型和 2 型糖尿病之间存在差异。和田等人的研究。文件显示，在 2 型糖尿病动物模型中，SGLT2 抑制剂主要通过传入小动脉收缩（由腺苷/A1 受体途径介导的过程）减轻肾小球过度滤过。这一观察结果与 1 型糖尿病中发现的机制一致，主张在 1 型和 2 型糖尿病中采用类似的方法。